Cognition Therapeutics, Inc. Files 8-K: Key Updates & Insights from December 2024
Based on the provided section of the financial report, here are the key extracted details:
- Entity Identification:
- Company Name: Cognition Therapeutics, Inc.
- CIK: 0001455365
- IRS Number: 13-4365359
- Location: 2500 Westchester Avenue, Purchase, NY 10577
- Phone Number: 412-481-2210
- Stock Exchange: NASDAQ
- Ticker Symbol: CGTX
- Report Type:
- Filing Type: 8-K (a report of unscheduled material events or corporate changes).
- Filing Date:
- Filing Date: December 18, 2024
- Report Period: The report covers the date December 18, 2024.
- Stock Information:
- Common Stock Par Value: $0.001 per share.
- Units of Measure:
- The report uses multiple units of measure:
- Currency: USD (United States Dollar)
- Shares: Common stock shares
- Schema Reference:
- The filing references an XBRL schema:
cgtx-20241218.xsd.
Insights:
- The company is likely reporting a significant event or change on December 18, 2024, as indicated by the 8-K filing.
- The low par value of the common stock ($0.001) suggests a potentially growth-oriented company, often seen in biotech or tech startups.
- Being listed on NASDAQ indicates that Cognition Therapeutics, Inc. meets certain financial and regulatory standards, which can enhance credibility with investors.
- The presence of a detailed schema reference indicates compliance with SEC requirements for electronic filings, ensuring structured data presentation for better analysis.
This information is crucial for stakeholders assessing Cognition Therapeutics, Inc.'s financial status, regulatory compliance, and market activity.